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Abstract Cancer remains a major cause of death in the
world to date. A variety of anticancer drugs have been used
in clinical chemotherapy, acting on the particular onco-
genic abnormalities that are responsible for malignant
transformation and progression. Interestingly, some of
these anticancer drugs are developed from natural sources
such as plants, marine organisms, and microorganisms.
Over the past decades, a family of naturally occuring
molecules, namely sesterterpenoids, has been isolated from
different organisms and they exhibit significant potential in
the inhibition of tumor cells in vitro, while the molecular
targets of these compounds and their functional mechan-
isms are still obscure. In this review, we summarize and
discuss the functions of these sesterterpenoids in the inhi-
bition of cancer cells. Moreover, we also highlight and
discuss chemical structure–activity relationships of some
compounds, demonstrating their pervasiveness and impor-
tance in cancer therapy.
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Introduction: overview of sesterterpenoids
and their biological functions
Natural compounds sourced from different organisms ex-
hibit immense structural diversity and possess extensively
biological activities against malaria, inflammation, multi-
ple types of cancer, and many infectious diseases. Many of
these compounds have been used in clinical therapy, such
as etoposide [1], vincristine [2], irinotecan [3], and pacli-
taxel [4]. As the largest subclass of natural products, ac-
counting for more than 40,000 individual compounds,
terpenoids also exhibit diverse biological functions, par-
ticularly in the prevention and therapy of multiple cancer
types such as skin, lung, pancreatic, colon, and prostate
cancer [5, 6]. Based on the number of isoprene units
building their parent terpene scaffold, terpenoids can be
generally categorized into hemiterpenoids (C5), monoter-
penoids (C10), sesquiterpenoids (C15), diterpenoids (C20),
sesterterpenoids (C25), triterpenoids (C30), tetraterpenoids
(C40), and polyterpenoids (more than C40) [7, 8]. Among
these terpenoids, pharmaceutical effects against tumor cells
have been extensively reported in monoterpenoids and
triterpenoids [9–11], which exhibit the ability to suppress
the growth of cancer cells by inducing tumor cell differ-
entiation and apoptosis, and inhibiting tumor angiogenesis,
invasion, and metastasis [12–14]. In recent years, sestert-
erpenoids, a small subgroup of terpenoids, have been
widely isolated from different organisms, and also exhibit
diverse biological properties involving anti-inflammatory,
antimicrobial, anti-feedant, antitubercular, and anti-biofilm
formation [7, 8]. Some sesterterpenoids even possess
multifunctional activities. For instance, manoalide has both
anti-inflammatory and antimicrobial activities [7, 8]. Im-
portantly, many sesterterpenoids can suppress the growth
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promising candidates for anticancer drugs [7, 8, 15].
However, their functional mechanisms and molecular tar-
gets are barely known to date.
Sesterterpenoids commonly harbor C25 carbon skeletons
in their molecular structures. However, some compounds
that contain C21–C24 are also grouped into sesterterpenoids,
termed as norsesterterpenoids [7, 8]. So far, nearly 1,000
sesterterpenoids have been isolated from terrestrial fungi,
lichens, higher plants, insects, and various marine organ-
isms, particularly sponges [8, 16]. Based on the carbocycle
numbers contained in their molecular structures, sesterter-
penoids can be broadly classified into 6 subgroups: linear,
monocarbocyclic, bicarbocyclic, tricarbocyclic, tetracarbo-
cyclic, and miscellaneous sesterterpenoids [7, 8, 17]. All of
these six subclasses of sesterterpenoids have been reported to
exhibit significant cytotoxicities against tumor cells.
Linear sesterterpenoids and their cytotoxicities
against tumor cells
Although the structures of linear sesterterpenoids are very
simple, many of them possess significant cytotoxicities
against human tumor cells, with unknown mechanisms of
action. Four C22 furanosesterterpenoids isolated from the
Ircinia species of sponges, including irciformonins C (1), D
(2), 15-acetylirciformonin B (3), and 10-acetylirciformonin
B (4) [18], have been reported to significantly inhibit dif-
ferent human cancer cells, in which compounds (1) and (2)
suppress the growth of colon tumor cells, and compounds
(3) and (4) display notable cytotoxic activities against
K562, DLD-1, HepG2, and Hep3B cancer cells [8, 19].
Some haslenes (5–7) (from Haslea ostrearia) that house
C25 highly branched isoprenoid (HBI) alkenes appear to
possess cytostatic effects on human lung cancer cells
in vitro [20, 21]. Four furanosesterterpenes isolated from
the marine sponge Ircinia oros, ircinin-1 (8) [22], (7E, 12E,
18R, 20Z)-variabilin (9) [23], (8E, 13Z, 18R, 20Z)-stro-
bilinin (10) [23], and (7E, 13Z, 18R, 20Z)-felixinin (11)
[23], have been demonstrated to show cytotoxicities
against SK–MEL-2 human cancer cells by inducing cell
cycle arrest and apoptosis [8, 22]. Supplementation with
ircinin-1 (8) can lead to G1 phase arrest during cell cycle
progression, and this process is associated with a marked
decrease in protein levels of cyclin D, CDK4 and CDK6
[22]. Ircinin-1 can also induce the release of cytochrome c,
activation of caspase-3 and caspase-9, and upregulation of
Fas and Fas-L [22].
Moreover, furospinosulin-1 (12), a marine-sponge-
derived furanosesterterpene, exhibits activity against
DU145 human prostate cancer cells by inhibiting cell
proliferation [24]. Subsequent study has demonstrated that
furospinosulin-1 could suppress the expression of insulin-
like growth factor-2 (IGF-2) [24], which is a hypoxia-in-
ducible angiogenic factor and is selectively induced under
hypoxic conditions through inhibiting the binding of nu-
clear proteins to the Sp1 consensus sequence in the IGF-2
promoter region [24] (Fig. 1).
Fig. 1 Structures of linear
sesterterpenoids 1–12
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Monobocyclic sesterterpenoids and their
cytotoxicities against tumor cells
A variety of monobocyclic sesterterpenoid compounds have
also been demonstrated to exhibit significant cytotoxicities.
However, little is known about their functional mechanisms.
24-n-Propyl-O-manoalide (13), a derivative of manoalide,
was isolated from Luffariella species [25] and showed sig-
nificant cytotoxicity against HCT-116 cancer cells [25].
Some monobocyclic sesterterpenoids isolated from Di-
acarnus cf. spinopoculum, including ent-muqubilin A (14),
ent-epimuqubilin A (15), nuapapuin B (16), epi-nuapapuin
B (17), muqubilin B (18), and epi-muqubilin B (19), possess
cytotoxicities against NCI-60 cells [8, 26]. The diacarnox-
ides A (20) and B (21), isolated from Diacarnus levii, dis-
play cytotoxicities against T47D breast tumor cells by
inhibiting HIF-1 (hypoxia-inducible factor) activation under
hypoxic conditions [27]. It should be noticed here that the
activity of HIF-1 is involved in angiogenesis required for
tumor cell growth, and thus HIF-1 inhibitors are now under
investigation for anticancer effects [28]. The aplysinoplides
A–C (22–24) identified in Aplysinopsis digitata have cyto-
toxicities against P-388 mouse leukemia cells [29]. Luf-
fariolides A–J (25–33), obtained from Luffariella species of
marine sponge, exhibit significant cytotoxicities against
murine lymphoma L1210 cells. Of them, luffariolides A
(25), B (26), E (29), and F (30) show the most significant
activities [15, 30, 31] (Fig. 2).
Bicarbocyclic sesterterpenoids and their
cytotoxicities against tumor cells
Sesterterpenoids with a bicarbocyclic skeleton in many
compounds show structures reminiscent of the clerodane
and labdane diterpenoids [7, 8]. Kohamaic acid A (34)
[32], a compound isolated from Ircinia species of marine
sponge, functions as a powerful inhibitor of DNA
Fig. 2 Structures of monobocyclic sesterterpenoids 13–33
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polymerases [32], which are specialized for DNA replica-
tion and repair, and can help cancer cells tolerate DNA
damage [33]. Some of these enzymes have been developed
as viable targets for therapeutic strategies of cancer [33].
The derivatives of kohamaic acid A have also been shown
to prevent the growth of HL-60 human cancer cells through
inhibition of DNA replication and repair processes [34].
Several sesterterpenes, including thorectandrols A–D (35–
38) [35, 36] and palauolol (39) [37], share similar chemical
structures and also display cytotoxicities against a variety
of cancer cell lines [38]. Palauolol shows significant in-
hibitory activity against MCF-7, SNB-19, COLO-205,
KM12, MOLT-4, H460, A549, LOX, and MALME-3 tu-
mor cell lines, whereas thorectandrols A–D only display
weak activities against some of them [38]. Two other
sesterterpenoids (40 and 41), which were isolated from the
Coscinoderma species of sponge, exhibit moderate cyto-
toxicities against K562 cells [39] (Fig. 3).
Tricarbocyclic sesterterpenoids and their
cytotoxicities against tumor cells
Many sesterterpenoids that possess tricarbocyclic skeleton
have also been found to show cytotoxicities. Ophiobolins,
including ophiobolin A (42), 6-epi-ophiobolin A (43),
3-anhydro-6-epi-ophiobolin A (44), and ophiobolin I (45),
were isolated from Bipolaris species [40]. All of them have
cytotoxic activities against A-549, HT-29, and Mec-20
human tumor cells [40]. Mechanistic analysis indicates that
ophiobolin A suppresses proliferation and migration of
cancer cells, and it triggers a paraptosis-like cell death
through disrupting internal potassium ion homeostasis [41].
Both 43 and 44 exhibit significant cytotoxicities, whereas
ophiobolin I only shows weak activity against tumor cells
in comparison with compound 43 [7].
Aurorals (46–47) isolated from the sponge Rhabdastrella
globostellata were found to exhibit cytotoxicities against
KB cells [42]. Seven sesterterpenoids isolated from Pet-
rosaspongia nigra, namely petrosaspongiolides C–H (50–
55) and L (56), exhibit cytotoxicities against NSCLC-N6
human bronchopulmunary non-small-cell-lung carcinoma
cells [43]. The scalarane-related sesterterpene hyatolides A
(57) identified in the sponge Hyatella intestinalis has shown
activity as a growth inhibitor of several tumor cell lines such
as MDA-MB-231, A-549, and HT-29 [44]. Five iso-
malabaricane-derived natural products from Rhabdastrella
globostellata, namely globostelletins C–G (58–62), display
different activities against human tumor cell lines such as
A549, BGC-823, HCT-8, Bel-7402, and A2780 [45]. A
globostelletin-derived compound, namely rhabdastrellic
acid A (63), has been shown to have potent inhibition against
HL-60 cells by inducing apoptosis in M/G2 phase [46].
Further studies indicate that rhabdastrellic acid A can inhibit
proliferation of Hep3B and A549 tumor cells and induce
autophagy-associated cell death through blocking the Akt
pathway [46]. This process can be negated by transfection
with constitutively active Akt plasmid [46] (Fig. 4).
Tetracarbocyclic sesterterpenoids and their
cytotoxicities against tumor cells
Tetracarbocyclic sesterterpenoids are emerging as a class
of attractive compounds exhibiting significant activities
against tumor cells. Scalaranes, the most common sestert-
erpenoids, have been reported to possess broad and sig-
nificant cytotoxicities against cancer cells [47]. Among
them, three scalaranes isolated from Haloragis erecta,
namely salmahyrtisol B (64), 3-acetyl- and 19-acetyl-ses-
terstatin (65 and 66), show significant cytotoxicities against
P-388, A-549, and HT-29 tumor cells [47]. A pentacyclic
sesterterpene isolated from Haloragis erecta, namely ses-
terstatin 6 (67), shows significant cytotoxicity against
murine leukemia (P-388) and some human tumor cell lines,
including BXPC-3, KAT-4, SW1736, NCI-H460, FADU,
Fig. 3 Structures of
bicarbocyclic sesterterpenoids
34–41
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and DU-145 [48]. Hyatelactam (68), isolated from Hyatella
intestinalis, has been shown to inhibit HT-29 tumor cells
[44]. Hippospongide B (69), which was isolated from a
Hippospongia species of sponge, exhibits significant cyto-
toxicity against DLD-1, HCT-116, T-47D, and K562 tumor
cells [49]. Seven other novel scalarane sesterterpenes iso-
lated from Psammocinia species, namely 12-deacetoxy-23-




heteronemin (75), and 12-deacetoxy-23-acetoxy-19-O-
acetylscalarin (76), exhibit cytotoxicities against human
renal cancer cell lines (A498, ACHN), pancreatic cancer
cell lines (MIA-paca, PANC-1), and noncancerous monkey
cell line (CV-1) in vitro [50].
Hyatelone A (77), 19,20-di-O-acetylhyatelone B (78),
and 20-O-acetylhyatolide C (79) posses cytotoxicities
against MDA-MB-231, A-549, and HT-29 tumor cells [44].
Beside anti-feedant and anti-inflammatory properties,
scalarenedial (80) also displays cytotoxicity against HL-60
cells [51]. 12-O-Deacetylnorscalaral B (81), isolated from
the sponge Hyatella intestinalis, exhibits activity to inhibit
the growth of MDA-MB-231, A-549, and HT-29 tumor
cells [44]. Sesterterpene polyols, the mangicols A–G (82–
88), which possess unprecedented spirotricyclic skeletal
components, show only weak-to-modest cytotoxicities
against a variety of cancer cell lines in vitro, especially for
NCI-60 cells [52]. Heteronemin (89), a spongean
sesterterpenoid isolated from Hyrtios species, inhibits
TNFa-induced NF-jB (nuclear factor kappa-B) activation
through proteasome inhibition and induces apoptotic cell
death [53, 54]. Heteronemin can affect a variety of cellular
processes including cell cycle, apoptosis, the mitogen-ac-
tivated protein kinases (MAPKs) pathway and the NF-jB
signaling cascade, thereby contributing to tumor cell
growth inhibition [53, 54]. PHC-2–PHC-7 (90–95), which
were isolated from Phyllospongia chondrodes, can increase
hemoglobin production in human chronic myelogenous
leukemia cell line K562 by inducing erythroid differen-
tiation [55]. Neomangicols A (96) and B (97) are cytotoxic
to HCT-116 human colon carcinoma in vitro [56].
Moreover, scalaradial (80) and cacospongionolide A
(98) should be particularly noted; they are isolated from
Cacospongia scalaris and Fasciospongia cavernosa
marine sponges, respectively, and can significantly inhibit
the growth of T47D, A431, HeLa, and HCT116 cells
with different mechanisms [57]. Detailed studies indicate
that treatment of T47D cells with scalaradial or ca-
cospongionolide can lead to increased DNA migration
and fragmentation [57]. Incubation of HCT116 and HeLa
cells with scalaradial or cacospongionolide results in in-
creased pro-apoptotic protein levels and the loss of mi-
tochondrial transmembrane [57], implying the activation
of apoptosis signaling. These results suggest that
scalaradial and cacospongionolide may represent new
promising compounds for inhibiting cancer cell prolif-
eration (Fig. 5).
Fig. 4 Structures of
tricarbocyclic sesterterpenoids
42–63
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Fig. 5 Structures of tetracarbocyclic sesterterpenoids 64–98
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Miscellaneous sesterterpenoids and their
cytotoxicities against tumor cells
Studies also demonstrate that miscellaneous sesterter-
penoids exhibit significant cytotoxicities against tumor
cells. Salmahyrtisol A (99), which was isolated from
Hyrtios erecta, exhibits significant cytotoxicity against
murine leukemia (P-388), A-549, and HT-29 human
cancer cells [58]. Terpestacin (100), a miscellaneous
compound, was isolated from a Phomopsis species of
fungus [59]. Mechanistic study indicates that terpestacin
suppresses tumor angiogenesis by targeting UQCRB of
mitochondrial complex III in the mitochondrial respiratory
chain, thereby causing the inhibition of hypoxia-induced
reactive oxygen species and cellular oxygen sensing [59,
60] (Fig. 6).
Chemical structure–activity relationships
Some sesterterpenes share similar chemical structures but
exhibit distinct cytotoxic activities against cancer cells.
Thus, it will be interesting and helpful to investigate the
relationship between chemical structure and activity.
Although many sesterterpenes have been found to show
cytotoxicities to tumor cells, it is impossible to compare
their activities meaningfully since different cancer cell
lines were used for different compounds in cytotoxic
assays. Here, we track some sesterterpenes isolated by
Dr. Liu’s group (from South China Sea Institute of
Oceanology) in the past years, and try to find factors
affecting their activities (Table 1), thereby providing
guidance for modifying the chemical structure of ses-
terterpenes and obtaining derivatives with more bioac-
tivity in the future.
C-21 structures and cytotoxicities against tumor
cells
Sarcotin A, a compound isolated from Sarcotragus species,
possesses a pair of epimers, C-21R (101) and C-21S (102)
[61]. Cytotoxicity analysis indicates that the C-21R epimer
is much more cytotoxic than the C-21S epimer. Consistent
with this, sarcotin B (103) and isopalinurin (104), and the
other two furanosesterterpenes (105 and 106) from Psam-
mocinia species also show much higher cytotoxicity to
cancer cells in their C-21R epimers than their respective
C-21S epimers [62] (Fig. 7)
c-Hydroxybutenolide moiety and cytotoxicities
against tumor cells
Some cacospongionolides (98, 107–108) share similar
chemical structures with thorectandrols, but exhibit sig-
nificantly higher cytotoxicities than thorectandrols. Their
structure comparison suggests a possible relationship be-
tween the c-hydroxybutenolide moiety and cytotoxicity
[57, 63]. Furthermore, some sesterterpenes including a
norsesterterpenoid compound (109), sarcotin I (110) and
sarcotin J (111) [61, 64], share similar chemical structures
with compound 101. However, their cytotoxicities against
cancer cells are weaker than compound 101, which con-
tains a c-hydroxybutenolide moiety. These results clearly
demonstrate that the c-hydroxybutenolide moiety is nec-
essary for the activities of sesterterpenes, and the opening
ring of c-hydroxybutenolide may also cause the decrease in
cytotoxicity (Fig. 8).
Furan moiety and cytotoxicities against tumor cells
The furan moiety also displays a relevance to cytotoxicity.
Comparison of the chemical structures and cytotoxicities of
compounds 109 and 112–113 indicates that sesterterpenes
containing a furan moiety have increased cytotoxicity
when the furan moiety is oxygenated to form unsaturated
lactone or dihydrofuran [63, 64]. Moreover, sesterterpenes
8 and 114–117 containing two furan moieties show higher
cytotoxicities than those compounds (118–120) that con-
tain only one furan moiety [65]. That is to say, the more
furan rings means stronger cytotoxicities, and the oxidation
of a furan ring at an appropriate degree might also improve
the cytotoxicities of sesterterpenes (Fig. 9).
Pyrrole moiety and cytotoxicities against tumor cells
The pyrrolosesterterpenes are chemically unique com-
pounds, and incorporate a pyrrole ring to replace the furan
ring. The pyrrole moiety also displays correlation with
cytotoxicity in sesterterpenes. Comparison of the chemical
structures and activities of compound 118 and sesterter-
penes 121–126 indicates increased cytotoxicity in com-
pounds harboring a pyrrole moiety [61]. However,
sesterterpenes carrying a b-substituted lactam ring (127)
instead of the a-substituted one exhibit dramatically de-
creased activity [61]. Moreover, an alkyl moiety attached
Fig. 6 Structures of miscellaneous sesterterpenoids 99–100
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on the N-atom of the pyrrole ring is also required for cy-
totoxicity. For instance, some sesterterpenes (128–131), in
which the alkyl moieties are substituted by carboxylic acid
sodium, show completely absent cytotoxicity [64]
(Fig. 10).
Double bonds and cytotoxicities against tumor cells
The double bonds within the sesterterpenes also have sig-
nificant effects on cytotoxicity, and the effect is complicated.
For instance, comparison of cytotoxicities of two fura-
nosesterterpenes (9 and 10) isolated from a Psammocinia
species of marine sponge [60] clearly indicates that com-
pound 10 which carries a double bond in D12,13 has much
higher cytotoxicity than 9 [60]. Furthermore, the con-
figuration of double bonds also plays important roles for the
activities of compounds. Some E-difuranosesterterpenes
(115 and 117) have been reported to display lower activities
than their respective Z-difuranosesterterpenes (114 and 116)
[65]. The different position of double bonds may lead to
different activities. For instance, compounds 105 and 106
share similar structures, but have different positions of
double bonds. Interestingly, compound 105 exhibits higher
cytotoxicity than 106 in SK-MEL-2, SK-OV-3, and XF498
Table 1 Cytotoxic activities of
compounds
Compound Tumor cell lines Reference
A549 SK-MEL-2 SK-OV-3 HCT15 XF498
101 29.7 [30 22.1 27.2 24.8 [61]
102 12.3 5.6 9.6 6.5 9.8 [61]
103 10.1 7.8 11.3 9.0 8.9 [61]
104 5.2 4.4 10.2 5.4 5.1 [61]
105 [30 10.7 16.5 [30 10.0 [62]
106 24.1 19.0 18.6 23.5 22.1 [62]
109 19.4 10.9 [30 21.7 [30 [61, 64]
110 24.8 25.7 23.3 23.7 25.9 [61, 64]
111 18.1 7.8 10.0 8.7 24.3 [61, 64]
112 24.1 15.2 7.6 10.5 20.1 [61, 65]
113 8.2 7.5 12.6 19.2 7.8 [61, 65]
114 3.7 9.0 6.6 6.9 5.4 [61, 65]
115 5.0 10.2 9.4 9.8 6.5 [61, 65]
116 3.8 5.9 5.9 4.7 3.7 [61, 65]
117 3.8 8.4 6.2 7.3 5.0 [61, 65]
118 29.7 [30 22.1 27.2 24.8 [61, 65]
119 10.1 7.8 11.3 9.0 9.0 [61, 65]
120 16.89 16.3 26.8 27.5 20.4 [61, 65]
121 15.1 4.1 5.3 5.0 5.5 [61]
122 4.3 3.4 4.0 3.8 3.9 [61]
123 6.3 4.3 6.7 4.9 5.2 [61]
124 16.8 4.8 13.1 5.4 10.5 [61]
125 19.0 3.8 6.9 5.3 5.4 [61]
126 27.1 15.9 26.8 22.3 25.2 [61]
127 [30 13.2 25.9 21.6 [30 [61]
128 [30 10.9 [30 33.0 [30 [64]
129 [30 [30 [30 [30 [30 [64]
130 [30 [30 [30 [30 [30 [64]
131 [30 [30 [30 [30 [30 [64]
9 [30 7.5 [30 20.5 28.1 [60]
10 7.5 12.3 4.8 11.7 10.5 [60]
Data expressed as ED50 values (lg/mL)
A549 human lung cancer cell line, SK-MEL-2 human skin cancer cancer cell line, SK-OV-3 human ovarian
cancer cell line, HCT15 human colon cancer cell line, XF498 human CNS cancer cell line
262 J Nat Med (2015) 69:255–266
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tumor cells [62]. These results indicate that the D8(10),11(12)
conjugated double bondsmay increase cytotoxicity, whereas
the D15(16),17(18) double bonds possibly decrease activity.
Taken together, the characteristics of double bonds including
number, position and configuration show significant effects
on the cytotoxicity of sesterterpenes.
Challenges and future directions
One challenge for cancer chemotherapy is the lack of ef-
fective antitumor drugs. The traditional chemotherapeutic
medicines cannot selectively kill cancer cells, and conse-
quently cause serious side effects including immuno-
Fig. 7 Structures of C-21-
containing sesterterpenoids
101–106




Fig. 9 Structures of furan
moiety-containing
sesterterpenoids 112–120
J Nat Med (2015) 69:255–266 263
123
logical, neurological, metabolic, and infectious diseases.
Developing compounds from natural sourcea as anticancer
drugs is a new strategy to overcome or decrease these side
effects. Interestingly, many sesterterpenoids from natural
sources have been reported to exhibit strong cytotoxicities
by inhibiting cancer cell proliferation and/or inducing cell
death. These sesterterpenoids are attracting more interest
and may represent new promising compounds in cancer
therapy.
Although many sesterterpenoids have been reported to
exhibit significant cytotoxicities in vitro, few studies have
provided insights into their molecular targets and
mechanisms. Thus, it is necessary to further explore studies
on signal transduction involved in cancer pathways, the
in vivo physiological roles and the systematic structure–
activity relationships of these compounds. The detailed
mechanistic understanding of sesterterpenoids may provide
critical insights into future development and investigation
of cancer therapeutics with higher specificity and selec-
tivity. The commendable understanding of relationship
between structures and activities can, in turn, help us to
chemically modify and synthesize powerful compounds
against tumor cells. Furthermore, we anticipate establish-
ing a sesterterpenoid compound-bank to screen effective
and specific compounds against various diseases, including
but not limited to cancer. Sesterterpenoids may be used in
combination with other chemotherapeutic drugs to increase
effectiveness and decrease doses of individual compounds,
therefore reducing side effects.
Acknowledgments This work was supported by the National Nat-
ural Science Foundation of China (31470395). We would like to
express our gratitude to Dr. Li Qiu for critically reading the manu-
script and for facilitating discussions. We apologize to our colleagues
whose work is not cited due to space limits.
Conflict of interest There is no conflict of interest to be declared by
the authors.
References
1. Hande KR (1998) Etoposide: four decades of development of a
topoisomerase II inhibitor. Eur J Cancer 34:1514–1521
2. Boslooper K, Kibbelaar R, Storm H, Veeger NJ, Hovenga S,
Woolthuis G, van Rees B, de Graaf E, van Roon E, Kluin-
Nelemans HC (2014) Treatment with rituximab, cyclophos-
phamide, doxorubicin, vincristine and prednisolone is beneficial
but toxic in very elderly patients with diffuse large B-cell lym-
phoma: a population-based cohort study on treatment, toxicity
and outcome. Leuk Lymphoma 55:526–532
3. Morland B, Platt K, Whelan JS (2014) A phase II window study
of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-
E.W.I.N.G. study. Pediatr Blood Cancer 61:442–445
4. Cui L, Liu XX, Jiang Y, Liu JJ, Zhou XR, He XJ, Chen J, Huang
XE (2014) Phase II study on dose escalating schedule of pacli-
taxel concurrent with radiotherapy in treating patients with lo-
cally advanced non-small cell lung cancer. Asian Pac J Cancer
Prev 15:1699–1702
5. Gershenzon J, Dudareva N (2007) The function of terpene natural
products in the natural world. Nat Chem Biol 3:408–414
6. Degenhardt J, Kollner TG, Gershenzon J (2009) Monoterpene
and sesquiterpene synthases and the origin of terpene skeletal
diversity in plants. Phytochemistry 70:1621–1637
7. Liu Y, Wang L, Jung JH, Zhang S (2007) Sesterterpenoids. Nat
Prod Rep 24:1401–1429
8. Wang L, Yang B, Lin XP, Zhou XF, Liu Y (2013) Sesterter-
penoids. Nat Prod Rep 2013(30):455–473
9. Huang M, Lu JJ, Huang MQ, Bao JL, Chen XP, Wang YT (2012)
Terpenoids: natural products for cancer therapy. Expert Opin
Investig Drugs 21:1801–1818
10. Rabi T, Bishayee A (2009) Terpenoids and breast cancer
chemoprevention. Breast Cancer Res Treat 115:223–239
11. Thoppil RJ, Bishayee A (2011) Terpenoids as potential chemo-
preventive and therapeutic agents in liver cancer. World J
Hepatol 3:228–249
12. Sagar SM, Yance D, Wong RK (2006) Natural health products
that inhibit angiogenesis: a potential source for investigational
new agents to treat cancer - Part 1. Curr Oncol 13:14–26
13. Kuttan G, Pratheeshkumar P, Manu KA, Kuttan R (2011) Inhi-
bition of tumor progression by naturally occurring terpenoids.
Pharm Biol 49:995–1007
14. Yang H, Dou QP (2010) Targeting apoptosis pathway with nat-
ural terpenoids: implications for treatment of breast and prostate
cancer. Curr Drug Targets 11:733–744
Fig. 10 Structures of pyrrole
moiety-containing
sesterterpenoids 121–131
264 J Nat Med (2015) 69:255–266
123
15. Ebada SS, Lin W, Proksch P (2010) Bioactive sesterterpenes and
triterpenes from marine sponges: occurrence and pharmaco-
logical significance. Mar Drugs 8:313–346
16. Li GY, Li BG, Yang T, Yin JH, Qi HY, Liu GY, Zhang GL
(2005) Sesterterpenoids, terretonins A-D, and an alkaloid, aster-
relenin, from Aspergillus terreus. J Nat Prod 68:1243–1246
17. Hog DT, Webster R, Trauner D (2012) Synthetic approaches
toward sesterterpenoids. Nat Prod Rep 29:752–779
18. Shen YC, Liaw CC, Ho JR, Khalil AT, Kuo YH (2006) Isolation
of aureol from Smenospongia sp. and cytotoxic activity of some
aureol derivatives. Nat Prod Res 20:578–585
19. Su JH, Tseng SW, Lu MC, Liu LL, Chou Y, Sung PJ (2011)
Cytotoxic C21 and C22 terpenoid-derived metabolites from the
sponge Ircinia sp. J Nat Prod 74:2005–2009
20. Rowland SJ, Belt ST, Wraige EJ, Masse G, Roussakis C, Robert
JM (2001) Effects of temperature on polyunsaturation in cyto-
static lipids of Haslea ostrearia. Phytochemistry 56:597–602
21. Allard WG, Belt ST, Masse G, Naumann R, Robert JM, Rowland
S (2001) Tetra-unsaturated sesterterpenoids (Haslenes) from
Haslea ostrearia and related species. Phytochemistry 56:795–800
22. Choi HJ, Choi YH, Yee SB, Im E, Jung JH, Kim ND (2005)
Ircinin-1 induces cell cycle arrest and apoptosis in SK-MEL-2
human melanoma cells. Mol Carcinog 44:162–173
23. Holler U, Konig GM, Wright AD (1999) Three new metabolites
from marine-derived fungi of the genera coniothyrium and mi-
crosphaeropsis. J Nat Prod 62:114–118
24. Arai M, Kawachi T, Setiawan A, Kobayashi M (2010) Hypoxia-
selective growth inhibition of cancer cells by furospinosulin-1, a
furanosesterterpene isolated from an Indonesian marine sponge.
Chem Med Chem 5:1919–1926
25. Zhou GX, Molinski TF (2006) Manoalide derivatives from a
sponge, Luffariella sp. J Asian Nat Prod Res 8:15–20
26. Sperry S, Valeriote FA, Corbett TH, Crews P (1998) Isolation and
cytotoxic evaluation of marine sponge-derived norterpene per-
oxides. J Nat Prod 61:241–247
27. Dai J, Liu Y, Zhou YD, Nagle DG (2007) Hypoxia-selective
antitumor agents: norsesterterpene peroxides from the marine
sponge Diacarnus levii preferentially suppress the growth of tu-
mor cells under hypoxic conditions. J Nat Prod 70:130–133
28. Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer
agents. Drug Discov Today 12:853–859
29. Ueoka R, Nakao Y, Fujii S, van Soest RW, Matsunaga S (2008)
Aplysinoplides A-C, cytotoxic sesterterpenes from the marine
sponge Aplysinopsis digitata. J Nat Prod 71:1089–1091
30. Kobayashi J, Zeng CM, Ishibashi M, Sasaki T (1993) Luf-
fariolides F and G, new manoalide derivatives from the Okina-
wan marine sponge Luffariella sp. J Nat Prod 56:436–439
31. Tsuda M, Endo T, Mikami Y, Fromont J, Kobayashi J (2002)
Luffariolides H and J, new sesterterpenes from a marine sponge
Luffariella species. J Nat Prod 65:1507–1508
32. Mizushina Y, Murakami C, Yogi K, Ueda K, Ishidoh T, Take-
mura M, Perpelescu M, Suzuki M, Oshige M, Yamaguchi T,
Saneyoshi M, Yoshida H, Sakaguchi K (2003) Kohamaic acid A,
a novel sesterterpenic acid, inhibits activities of DNA poly-
merases from deuterostomes. Biochim Biophys Acta 1648:55–61
33. Lange SS, Takata K, Wood RD (2011) DNA polymerases and
cancer. Nat Rev Cancer 11:96–110
34. Mizushina Y, Manita D, Takeuchi T, Sugawara F, Kumamoto-
Yonezawa Y, Matsui Y, Takemura M, Sasaki M, Yoshida H,
Takikawa H (2009) The inhibitory action of kohamaic acid A
derivatives on mammalian DNA polymerase beta. Molecules
14:102–121
35. Charan RD, McKee TC, Boyd MR (2001) Thorectandrols A and
B, new cytotoxic sesterterpenes from the marine sponge
Thorectandra species. J Nat Prod 64:661–663
36. Charan RD, McKee TC, Boyd MR (2002) Thorectandrols C, D,
and E, new sesterterpenes from the marine sponge Thorectandra
sp. J Nat Prod 65:492–495
37. Schmidt EW, Faulkner DJ (1996) Palauolol, a new anti-inflam-
matory sesterterpene from the sponge Fascaplysinopsis sp. from
Palau. Tetrahedron Lett 37:3951–3954
38. Sima P, Vetvicka V (2011) Bioactive substances with anti-neo-
plastic efficacy from marine invertebrates: Porifera and Coelen-
terata. World J Clin Oncol 2:355–361
39. Bae J, Jeon JE, Lee YJ, Lee HS, Sim CJ, Oh KB, Shin J (2011)
Sesterterpenes from the tropical sponge Coscinoderma sp. J Nat
Prod 74:1805–1811
40. Ahn JW, Lee MK, Choi SU, Lee CO, Kim BS (1998) Cytotoxic
ophiobolins produced by Bipolaris sp. J Micro Biotech
8:406–413
41. Bury M, Girault A, Megalizzi V, Spiegl-Kreinecker S, Mathieu
V, Berger W, Evidente A, Kornienko A, Gailly P, Vandier C,
Kiss R (2013) Ophiobolin A induces paraptosis-like cell death in
human glioblastoma cells by decreasing BKCa channel activity.
Cell Death Dis 4:e561
42. Bourguet-Kondracki ML, Longeon A, Debitus C, Guyot M
(2000) New cytotoxic isomalabaricane-type sesterterpenes from
the New Caledonian marine sponge Rhabdastrella globostellata.
Tetrahedron Lett 41:3087–3091
43. Paloma LG, Randazzo A, Minale L, Debitus C, Roussakis C
(1997) New cytotoxic sesterterpenes from the New Caledonian
marine sponge Petrosaspongia nigra (Bergquist). Tetrahedron
53:10451–10454
44. Hernandez-Guerrero CJ, Zubia E, Ortega MJ, Luis Carballo J
(2006) Sesterterpene metabolites from the sponge Hyatella in-
testinalis. Tetrahedron 62:5392–5400
45. Li J, Xu B, Cui J, Deng Z, de Voogd NJ, Proksch P, Lin W (2010)
Globostelletins A-I, cytotoxic isomalabaricane derivatives from
the marine sponge Rhabdastrella globostellata. Bioorg Med
Chem 18:4639–4647
46. Li DD, Guo JF, Huang JJ, Wang LL, Deng R, Liu JN, Feng GK,
Xiao DJ, Deng SZ, Zhang XS, Zhu XF (2010) Rhabdastrellic
acid-A induced autophagy-associated cell death through blocking
Akt pathway in human cancer cells. PLoS One 5:e12176
47. Roy MC, Tanaka J, de Voogd N, Higa T (2002) New scalarane
class sesterterpenes from an Indonesian sponge, Phyllospongia
sp. J Nat Prod 65:1838–1842
48. Pettit GR, Tan R, Cichacz ZA (2005) Antineoplastic agents. 542.
Isolation and structure of sesterstatin 6 from the Indian Ocean
sponge Hyrtios erecta. J Nat Prod 68:1253–1255
49. Chang YC, Tseng SW, Liu LL, Chou Y, Ho YS, Lu MC, Su JH
(2012) Cytotoxic sesterterpenoids from a sponge Hippospongia
sp. Mar Drugs 10:987–997
50. Hahn D, Won DH, Mun B, Kim H, Han C, Wang W, Chun T,
Park S, Yoon D, Choi H, Kang H (2013) Cytotoxic scalarane
sesterterpenes from a Korean marine sponge Psammocinia sp.
Bioorg Med Chem Lett 23:2336–2339
51. Corey EJ, Luo G, Lin LS (1997) A simple enantioselective
synthesis of the biologically active tetracyclic marine sesterter-
pene scalarenedial. J Am Chem Soc 119:9927–9928
52. Renner MK, Jensen PR, Fenical W (2000) Mangicols: structures
and biosynthesis of a new class of sesterterpene polyols from a
marine fungus of the genus Fusarium. J Org Chem 65:4843–4852
53. Schumacher M, Cerella C, Eifes S, Chateauvieux S, Morceau F,
Jaspars M, Dicato M, Diederich M (2010) Heteronemin, a
spongean sesterterpene, inhibits TNF alpha-induced NF-kappa B
activation through proteasome inhibition and induces apoptotic
cell death. Biochem Pharmacol 79:610–622
54. Cassiano C, Esposito R, Tosco A, Zampella A, D’Auria MV,
Riccio R, Casapullo A, Monti MC (2014) Heteronemin, a marine
J Nat Med (2015) 69:255–266 265
123
sponge terpenoid, targets TDP-43, a key factor in several neu-
rodegenerative disorders. Chem Commun (Camb) 50:406–408
55. Aoki S, Higuchi K, Isozumi N, Matsui K, Miyamoto Y, Itoh N,
Tanaka K, Kobayashi M (2001) Differentiation in chronic
myelogenous leukemia cell K562 by spongean sesterterpene.
Biochem Biophys Res Commun 282:426–431
56. Renner MK, Jensen PR, Fenical WJ (1998) Neomangicols:
structures and absolute stereochemistries of unprecedented
halogenated sesterterpenes from a marine fungus of the genus
Fusarium. J Org Chem 63:8346–8354
57. De Stefano D, Tommonaro G, Malik SA, Iodice C, De Rosa S,
Maiuri MC, Carnuccio R (2012) Cacospongionolide and
scalaradial, two marine sesterterpenoids as potent apoptosis-in-
ducing factors in human carcinoma cell lines. PLoS One
7:e33031
58. Youssef DT, Yamaki RK, Kelly M, Scheuer PJ (2002)
Salmahyrtisol A, a novel cytotoxic sesterterpene from the Red
Sea sponge Hyrtios erecta. J Nat Prod 65:2–6
59. Jung HJ, Shim JS, Lee J, Song YM, Park KC, Choi SH, Kim ND,
Yoon JH, Mungai PT (2010) Terpestacin inhibits tumor angio-
genesis by targeting UQCRB of mitochondrial complex III and
suppressing hypoxia-induced reactive oxygen species production
and cellular oxygen sensing. J Biol Chem 285:11584–11595
60. Jung HJ, Kwon HJ (2013) Exploring the role of mitochondrial
UQCRB in angiogenesis using small molecules. Mol BioSyst
9:930–939
61. Liu Y, Hong J, Lee CO, Im KS, Kim ND, Choi JS, Jung JH
(2002) Cytotoxic pyrrolo- and furanoterpenoids from the sponge
sarcotragus species. J Nat Prod 65:1307–1314
62. Choi K, Hong J, Lee CO, Kim DK, Sim CJ, Im KS, Jung JH
(2004) Cytotoxic furanosesterterpenes from a marine sponge
Psammocinia sp. J Nat Prod 67:1186–1189
63. De Rosa S, de Giulio A, Crispino A, Iodice C, Tommonaro G
(1997) Further bioactive sesterterpenes from the Tyrrhenian
sponge Fasciospongia cavernosa. Nat Prod Lett 10:267–274
64. Liu Y, Mansoor TA, Hong J, Lee CO, Sim CJ, Im KS, Kim ND,
Jung JH (2003) New cytotoxic sesterterpenoids and norsestert-
erpenoids from two sponges of the genus Sarcotragus. J Nat Prod
66:1451–1456
65. Liu Y, Bae BH, Alam N, Hong J, Sim CJ, Lee CO, Sim CJ, Kim
ND, Jung JH (2001) New cytotoxic sesterterpenes from the
sponge Sarcotragus species. J Nat Prod 64:1301–1304
266 J Nat Med (2015) 69:255–266
123
